Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum BDNF levels: a post-hoc analysis

Pharmacol Rep. 2021 Apr;73(2):594-603. doi: 10.1007/s43440-020-00203-1. Epub 2021 Jan 2.

Abstract

Rationale: Recently, the effects of ketamine on the circadian rhythm have suggested that ketamine's rapid antidepressant effects are associated with and without sleep disturbance improvement.

Objectives: Here, we evaluated the antidepressant efficacy of repeated ketamine infusions in patients with sleep disturbances.

Methods: This study included 127 patients with major depressive disorder or bipolar disorder who received ketamine treatments during a 12-day period. Sleep quality was assessed by the 17-item Hamilton Depression Rating Scale sleep disturbance factor (SDF) (items 4, 5 and 6). Serum brain-derived neurotrophic factor (BDNF) was measured at baseline, day 13 and day 26. This study was a post-hoc analysis.

Results: Significant differences were found in the HAMD-17 score at 13 post-infusion time points compared to baseline, as well as the scores in SDF score at each of the 7 post-infusion (4 h after each infusion excluded) time points among all patients. Logistic regression and linear correlation analyses revealed that a greater reduction in the SDF after 24 h of the first ketamine infusion resulted in a better antidepressant effect in the last two follow-up visits. Moreover, BDNF levels were significantly higher in sleep responders than in non-responders.

Conclusions: In the 127 patients, six ketamine infusions induced better therapeutic effects in sleep responders than in sleep non-responders and patients without sleep disturbances. The sleep response after repeated ketamine infusions was positively associated with high serum BDNF levels. Early sleep disturbance improvement (as early as 24 h after the first ketamine injection) may predict the antidepressant effect of repeated-dose ketamine.

Keywords: Antidepressant efficacy; Bipolar disorder; Brain-derived neurotrophic factor; Early prediction; HAMD-17; Ketamine; Major depressive disorder; Sleep disturbance; Sleep improvement.

Publication types

  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Antidepressive Agents / administration & dosage
  • Antidepressive Agents / pharmacology
  • Bipolar Disorder / drug therapy*
  • Brain-Derived Neurotrophic Factor / blood
  • Depressive Disorder, Major / drug therapy*
  • Excitatory Amino Acid Antagonists / administration & dosage
  • Excitatory Amino Acid Antagonists / pharmacology
  • Female
  • Humans
  • Infusions, Intravenous
  • Ketamine / administration & dosage
  • Ketamine / pharmacology*
  • Male
  • Psychiatric Status Rating Scales
  • Sleep Wake Disorders / drug therapy*
  • Time Factors
  • Treatment Outcome
  • Young Adult

Substances

  • Antidepressive Agents
  • Brain-Derived Neurotrophic Factor
  • Excitatory Amino Acid Antagonists
  • Ketamine
  • BDNF protein, human